Bezafibrate(CAS.NO:41859-67-0) improves markers of combined hyperlipidemia, effectively reducing LDL and triglycerides and improving HDL levels. The main effect on cardiovascular morbidity is in patients with the metabolic syndrome, the features of which are attenuated by bezafibrate. Studies show that in patients with impaired glucose tolerance, bezafibrate may delay progress to diabetes, and in those with insulin resistance it slowed progress in the HOMA severity marker. In addition, a prospective observational study of dyslipidemic patients with diabetes or hyperglycemia showed that bezafibrate significantly reduces haemoglobin A1c (HbA1c) concentration as a function of baseline HbA1c levels, regardless of concurrent use of antidiabetic drugs.
Drug interactions
Warfarin: Possible increased warfarin toxicity
Monoamine oxidase inhibitors (MAOIs): Possible liver damage
Antidiabetic drugs: Possible increased blood sugar lowering effect
Statin-type cholesterol-lowering drugs:Possible muscle damage
Orlistat: Manufacturer advises against concomitant use
Cholestyramine: Should be taken at least 2 hours apart from bezafibrate
Phenytoin: Possible increased phenytoin toxicity
Disease interactions : Consult your doctor before using this drug if you have
severe kidney or liver disease, an overactive thyroid gland, gallstones or a gall bladder disorder, a stomach ulcer, or if you have heart disease.
Overdose action : A small overdose is no cause for concern. In case of intentional large overdose, seek emergency medical attention.